SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
LUND, Sweden, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Active Biotech (Nasdaq Stockholm: ACTI) today announces that its partner Teva Pharmaceutical Industries Ltd, will amend the trial design in a Phase 2 study of laquinimod in Huntington's disease. The amendment consists of dropping the highest of three doses (1.5 mg/day) in the trial while keeping two remaining active doses (0.5 and
1 mg/day) unchanged. This is a precautionary measure in the interest of patient safety being suggested by Teva to the Data Safety Monitory Board (DSMB) for the LEGATO-HD trial.
The DSMB accepted the recommendation after reviewing data which observed cardiovascular incidents in patients receiving the high doses of laquinimod in two multiple sclerosis trials as reported on January 4, 2016. No cardiovascular events have been observed for any dose of the LEGATO-HD trial. Teva will continue in its commitment to study laquinimod in Huntington's disease.
Currently the mechanism of the cardiovascular events in the MS trials remains unknown. Although no specific time-to-event patterns have been identified, cardiovascular risk factors and demographics may play a role.
For further information, please contact:
Tomas Leanderson, President & CEO
Tel +46 46 19 20 95
Hans Kolam, CFO
Tel +46 46 19 20 44
Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in pivotal Phase 3 development for the treatment of relapsing remitting multiple sclerosis. Also, laquinimod is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Furthermore, commercial activities are conducted for the ISI, ANYARA and paquinimod projects. Please visit www.activebiotech.com for more information.
Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. This information was provided to the media for publication at 8:30 am CET on January 11, 2016.
Information regarding the clinical study LEGATO-HD http://hugin.info/1002/R/1977808/724195.pdf
HUG#1977808
